Jump to content

NASA Implementation Strategy for In Space Production Applications


Recommended Posts

  • Publishers
Posted

NASA’s In Space Production Applications (InSPA) implementation strategy consists of a multi-phase award process to demonstrate proof-of-concept, advance to high production quality, and ultimately to achieve scalability on a commercial low Earth orbit (LEO) destination or platform. InSPA seeks to identify awardees who propose promising manufacturing efforts in microgravity that will invigorate markets on Earth. These InSPA awards help the selected companies raise the technological readiness level of their products and move them to market, propelling U.S. industry toward the development of a sustainable, scalable, and profitable non-NASA demand for services and products manufactured in the microgravity environment of LEO for use on Earth.

NASA Award Process

On an annual and ongoing basis, NASA releases two calls for white papers by U.S. entities through Special Focus Area #1 (In Space Production Applications) of the NASA Research Announcement (NRA) NNJ13ZBG001N, “Research Opportunities for International Space Station Utilization.” Those entities with the highest rated white papers are then invited to submit a full proposal. After the proposal evaluation period, NASA makes selections, and awardees sign a Firm Fixed Price contract with NASA to develop and demonstrate their concept on the ISS National Laboratory. NRA white paper and proposal submissions are required at each phase of the lifecycle.

Access to ISS National Laboratory

Awardees are provided access to the ISS National Laboratory and all necessary on-orbit resources: upmass, downmass, U.S. Operating Segment (USOS) crew time, data transmission, and power, including flight manifesting and increment operations planning, at no cost. Payloads are subject to review and approval by the Center for the Advancement of Science in Space (CASIS), the operator of the ISS National Laboratory.

Award Phases

NASA has identified three InSPA phases (reference Figure 1) to characterize technology maturation from early concept studies through financially self-sustaining LEO production technologies.

image of flowchart showing the proposal submission process

InSPA Phase 1

Enable early proof-of-concept studies and/or basic flight hardware development and test through multiple demonstrations on parabolic, sub-orbital, and orbital missions on the ISS to achieve TRL of 6 and MRL of 3. Proposals should identify the improvements sought and describe the number and type of demonstration tests appropriate to achieve exit criteria for the Phase. The goals of Phase 1 (i.e., exit criteria) are:

  1. To demonstrate hardware performance and validate the scientific basis for the technology benefit in a LEO space environment. 
  2. To establish a minimum level of production control to repeatedly produce the intended product to a quality or performance level comparable to Earth-based controls or state of the art. 
  3. To refine the business case with preliminary revenue forecasts based on actual microgravity demonstrations and gain support from potential partners or investors to capture a moderate level of non-NASA investment for Phase 2.

InSPA Phase 2

Enable design maturation and advanced flight hardware development with additional demonstrations on ISS to achieve a TRL of 8 and MRL of 7. NASA has an expectation of some degree of cost-sharing in this phase (reference Cost Sharing guideline in section 1.2.3 of the NRA). The goals of Phase 2 (i.e., exit criteria) are:

  1. To demonstrate full control of hardware, environments, and processes to meet specific performance standards for the application.  These standards are often set by the customer and should be to a level of performance or quality within the application setting that is significantly better than possible on Earth. 
  2. To refine the business case to a level that successfully captures significant investor commitment for Phase 3.

InSPA Phase 3

Enable scaled flight hardware production on ISS or an alternative commercial LEO destination/platform to demonstrate commercial operations and end-to-end logistics model producing sufficient quantities to achieve a TRL of 9 and MRL of 9 and to close the business case. NASA expects a significant degree of cost-sharing by industry for a Phase 3 award (reference Cost Sharing guideline in Section 1.2.3 of the NRA). The goals of Phase 3 are:

  • Demonstrate scaling to commercial quantities and quality to support market demand, including supply chain and regulatory approvals. 
  • To establish formal agreements with U.S. LEO transportation and destination partners for transition to commercial operations. 
  • Begin transition to commercial platform(s) and achieve sustainable revenues. 
image of diagram showing three phases of proposal submission

Reference

NASA Research Announcement (NRA) NNJ13ZBG001N, “Research Opportunities for International Space Station Utilization”

View the full article

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Similar Topics

    • By NASA
      5 min read
      Avatars for Astronaut Health to Fly on NASA’s Artemis II
      An organ chip for conducting bone marrow experiments in space. Emulate NASA announced a trailblazing experiment that aims to take personalized medicine to new heights. The experiment is part of a strategic plan to gather valuable scientific data during the Artemis II mission, enabling NASA to “know before we go” back to the lunar surface and on to Mars.
      The AVATAR (A Virtual Astronaut Tissue Analog Response) investigation will use organ-on-a-chip devices, or organ chips, to study the effects of deep space radiation and microgravity on human health. The chips will contain cells from Artemis II astronauts and fly side-by-side with crew on their approximately 10-day journey around the Moon. This research, combined with other studies on the health and performance of Artemis II astronauts, will give NASA insight into how to best protect astronauts as exploration expands to the surface of the Moon, Mars, and beyond. 
      AVATAR is NASA’s visionary tissue chip experiment that will revolutionize the very way we will do science, medicine, and human multi-planetary exploration.”
      Nicky Fox
      Associate Administrator, NASA Science Mission Directorate
      “AVATAR is NASA’s visionary tissue chip experiment that will revolutionize the very way we will do science, medicine, and human multi-planetary exploration,” said Nicky Fox, associate administrator, Science Mission Directorate at NASA Headquarters in Washington. “Each tissue chip is a tiny sample uniquely created so that we can examine how the effects of deep space act on each human explorer before we go to ensure we pack the appropriate medical supplies tailored to each individual’s needs as we travel back to the Moon, and onward to Mars.”
      The investigation is a collaboration between NASA, government agencies, and industry partners, leveraging commercial expertise to gain a deeper understanding of human biology and disease. This research could accelerate innovations in personalized healthcare, both for astronauts in space and patients on Earth.
      Organ-on-a-chip: mimic for human health
      Organ chips, also referred to as tissue chips or microphysiological systems, are roughly the size of a USB thumb drive and used to help understand — and then predict — how an individual might respond to a variety of stressors, such as radiation or medical treatments, including pharmaceuticals. Essentially, these small devices serve as “avatars” for human organs. 
      Organ chips contain living human cells that are grown to model the structures and functions of specific regions in human organs, such as the brain, lungs, heart, pancreas, and liver — they can beat like a heart, breathe like a lung, or metabolize like a liver. Tissue chips can be linked together to mimic how organs interact with each other, which is important for understanding how the whole human body responds to stressors or treatments.
      Researchers and oncologists use human tissue chips today to understand how a specific patient’s cancer might react to different drugs or radiation treatments. To date, a standard milestone for organs-on-chips has been to keep human cells healthy for 30 days. However, NASA and other research institutions are pushing these boundaries by increasing the longevity of organ chips to a minimum of six months so that scientists can observe diseases and drug therapies over a longer period.
      Bone marrow as bellwether
      The Artemis II mission will use organ chips created using blood-forming stem and progenitor cells, which originate in the bone marrow, from Artemis II crew members.
      Bone marrow is among the organs most sensitive to radiation exposure and, therefore, of central importance to human spaceflight. It also plays a vital role in the immune system, as it is the origin of all adult red and white blood cells, which is why researchers aim to understand how deep space radiation affects this organ.
      Studies have shown that microgravity affects the development of bone marrow cells. Although the International Space Station operates in low Earth orbit, which is shielded from most cosmic and solar radiation by the Earth’s magnetosphere, astronauts often experience a loss of bone density. Given that Artemis II crew will be flying beyond this protective layer, AVATAR researchers also seek to understand how the combined stressors of deep space radiation and microgravity affect the developing cells.
      To make the bone marrow organ chips, Artemis II astronauts will first donate platelets to a local healthcare system. The cells remaining from their samples will contain a small percentage of bone marrow-derived stem and progenitor cells. NASA-funded scientists at Emulate, Inc., which developed the organ chip technology used in AVATAR, will purify these cells with magnetic beads that bind specifically to them. The purified cells will then be placed in the bone marrow chips next to blood vessel cells and other supporting cells to model the structure and function of the bone marrow.
      Investigating how radiation affects the bone marrow can provide insights into how radiation therapy and other DNA-damaging agents, such as chemotherapeutic drugs, impair blood cell formation. Its significance for both spaceflight and medicine on Earth makes the bone marrow an ideal organ to study in the Artemis II AVATAR project.
      Passenger for research
      “For NASA, organ chips could provide vital data for protecting astronaut health on deep space missions,” said Lisa Carnell, director of NASA’s Biological and Physical Sciences division at NASA Headquarters. “As we go farther and stay longer in space, crew will have only limited access to on-site clinical healthcare. Therefore, it’ll be critical to understand if there are unique and specific healthcare needs of each astronaut, so that we can send the right supplies with them on future missions.”
      During the Artemis II mission, the organ chips will be secured in a custom payload developed by Space Tango and mounted inside the capsule during the mission. The battery-powered payload will maintain automated environmental control and media delivery to the organ chips throughout the flight.
      For NASA, organ chips could provide vital data for protecting astronaut health on deep space missions.”
      Lisa Carnell
      Director of NASA’s Biological and Physical Sciences Division
      Upon return, researchers at Emulate will examine how spaceflight affected the bone marrow chips by performing single-cell RNA sequencing, a powerful technique that measures how thousands of genes change within individual cells. The scientists will compare data from the flight samples to measurements of crew cells used in a ground-based immunology study happening simultaneously. This will provide the most detailed look at the impact of spaceflight and deep space radiation on developing blood cells to date.
      Keep Exploring BPS Scientific Goals
      Goals



      Precision Health



      AVATAR



      Quantum Leaps


      Biological & Physical Sciences Division (BPS)

      NASA’s Biological and Physical Sciences Division pioneers scientific discovery and enables exploration by using space environments to conduct investigations not possible on Earth. Studying biological and physical phenomenon under extreme conditions allows researchers to advance the fundamental scientific knowledge required to go farther and stay longer in space, while also benefitting life on Earth.
      View the full article
    • By NASA
      A SpaceX Falcon 9 rocket carrying Northrop Grumman’s Cygnus XL spacecraft is launched on NASA’s Northrop Grumman Commercial Resupply Services 23 mission to the International Space Station on Sunday, Sept. 14, 2025.Credit: NASA NASA is sending more science, technology demonstrations, and crew supplies to the International Space Station following the successful launch of the agency’s Northrop Grumman Commercial Resupply Services 23 mission, or Northrop Grumman CRS-23.
      The company’s Cygnus XL spacecraft, carrying more than 11,000 pounds of cargo to the orbiting laboratory, lifted off at 6:11 p.m. EDT Sunday on a SpaceX Falcon 9 rocket from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida. This mission is the first flight of the larger, more cargo-capable version of the solar-powered spacecraft. 
      Cygnus XL is scheduled to be captured at 6:35 a.m. on Wednesday, Sept. 17, by the Canadarm2 robotic arm, which NASA astronaut Jonny Kim will operate with assistance from NASA astronaut Zena Cardman. Following capture, the spacecraft will be installed to the Unity module’s Earth-facing port for cargo unloading.
      The resupply mission is carrying dozens of research experiments that will be conducted during Expedition 73, including materials to produce semiconductor crystals in space and equipment to develop improvements for cryogenic fuel tanks. The spacecraft also will deliver a specialized UV light system to prevent the growth of microbe communities that form in water systems and supplies to produce pharmaceutical crystals that could treat cancer and other diseases.
      These are just a sample of the hundreds of scientific investigations conducted aboard the station in the areas of biology and biotechnology, Earth and space science, physical sciences, as well as technology development and demonstrations. For nearly 25 years, NASA has supported a continuous U.S. human presence aboard the orbiting laboratory, where astronauts have learned to live and work in space for extended periods of time. The space station is a springboard for developing a low Earth economy and NASA’s next great leaps in exploration, including Artemis missions to the Moon and American astronaut missions to Mars.
      NASA’s arrival, capture, and installation coverage are as follows (all times Eastern and subject to change based on real-time operations):
      Wednesday, Sept. 17
      5 a.m. – Arrival coverage begins on NASA+, Amazon Prime, and more.
      6:35 a.m. – Capture of Cygnus XL with the space station’s robotic arm.
      8 a.m. – Installation coverage begins on NASA+, Amazon Prime, and more.
      All coverage times are estimates and could be adjusted based on operations after launch. Follow the space station blog for the most up-to-date information.
      Cygnus XL is scheduled to remain at the orbiting laboratory until March 2026, before it departs and disposes of several thousand pounds of trash through its re-entry into Earth’s atmosphere, where it will harmlessly burn up. The spacecraft is named the S.S. William “Willie” C. McCool, in honor of the NASA astronaut who perished in 2003 during the space shuttle Columbia accident.
      Learn more about this NASA commercial resupply mission at:
      https://www.nasa.gov/mission/nasas-northrop-grumman-crs-23/
      -end-
      Josh Finch / Jimi Russell
      Headquarters, Washington
      202-358-1100
      joshua.a.finch@nasa.gov / james.j.russell@nasa.gov
      Steven Siceloff
      Kennedy Space Center, Fla.
      321-876-2468
      steven.p.siceloff@nasa.gov
      Sandra Jones / Joseph Zakrzewski
      Johnson Space Center, Houston
      281-483-5111
      sandra.p.jones@nasa.gov / joseph.a.zakrzewski@nasa.gov
      Share
      Details
      Last Updated Sep 14, 2025 LocationNASA Headquarters Related Terms
      International Space Station (ISS) Commercial Resupply ISS Research Johnson Space Center Northrop Grumman Commercial Resupply View the full article
    • By NASA
      NASA’s Northrop Grumman Commercial Resupply Services 23 Rendezvous and Capture
    • By Amazing Space
      NASA / SPACEX CRS-23 ISS RESUPPLY LAUNCH LIVE
    • By Amazing Space
      Live Video from the International Space Station (Seen From The NASA ISS Live Stream)
  • Check out these Videos

×
×
  • Create New...